Get the Stockscreener App
0.5968
14.06%
-0.0976
After Hours:
.51
-0.0868
-14.54%
Jaguar Health Inc stock is traded at $0.5968, with a volume of 2.65M.
It is down -14.06% in the last 24 hours and down -40.32% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
See More
Previous Close:
$0.6944
Open:
$0.677
24h Volume:
2.65M
Relative Volume:
16.88
Market Cap:
$2.93M
Revenue:
$29.57M
Net Income/Loss:
$-34.68M
P/E Ratio:
-0.000842
EPS:
-708.7214
Net Cash Flow:
$-7.58M
1W Performance:
-26.31%
1M Performance:
-40.32%
6M Performance:
-97.40%
1Y Performance:
-98.86%
1-Day Range:
$0.5716
$0.6808
1-Week Range:
$0.5716
$0.825
52-Week Range:
$0.5716
$77.63
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.5968 | 4.29M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Jaguar Health Faces Shareholder Quorum Challenge at Meeting - tipranks.com
Jaguar Health calls special meeting but fails to achieve quorum; no votes taken - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Jaguar Health progresses crofelemer for rare intestinal failure disorders - The Pharma Letter
JAGX Looks 99.4% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Jaguar Health plans MVID drug application for mid-2027 - Investing.com
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) - Yahoo Finance
Jaguar Health presents crofelemer data at ESPGHAN 2026 - scanx.trade
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Jaguar Animal Health Inc (JAGX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
News by ACCESS Newswire on TradingView, 2026-08-26 - TradingView
Jaguar Health launches Neonorm Dog for digestive support By Investing.com - Investing.com India
Jaguar Health: Sales And Marketing Spending Reduced More Than 99% After Future Pak Licensing Deal - pulse2.com
Form 424B3 Jaguar Health, Inc. - StreetInsider
Jaguar (JAGX) Latest: Finishes 1.74% Down at $0.86; Market Levels: Traders Can Monitor the $0.82-$0.90 Range for the Current SessionEarnings Miss Risk - vinanet.vn
Jaguar Health | 424B3: Prospectus - Moomoo
Jaguar Health revenue falls 59% to $1.2 million - grafa.com
Jaguar Health | 10-Q: Quarterly report - Moomoo
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and Strategic Pivot - GuruFocus
Jaguar Health (JAGX) Shifts Focus to Rare GI Treatments Amid Cha - GuruFocus
Jaguar Health Sets Q2 2027 NDA Submission Timeline for MVID Treatment - Minichart
Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Jaguar Health Posts Q2 Total Revenue $1.2 Million, EPS $-15.68 - TradingView
Jaguar Health Q2 loss narrows 96% as revenue falls 59% on licensing shift - scanx.trade
Q2 2026 Jaguar Health Inc Earnings Call Transcript - GuruFocus
Jaguar Health Reports $1.2 Million Q2 Revenue and $12.7 Million Net Loss - Quiver Quantitative
Jaguar Health Reports Second Quarter 2026 Financials - ACCESS Newswire
Jaguar Health FY26 Q2 net loss narrows 80.7% to USD 4.08 million; revenue rises 314% to USD 21.5 million - Bitget
Jaguar Health to hold Q2 2026 investor webcast on August 19 - scanx.trade
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates - Yahoo Finance
JAGX Q2'26 Earnings: EPS estimate is (52.15) USD - TradingView
Jaguar Health, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Jaguar Health Delays Quarterly SEC Filing - TipRanks
Jaguar Health (JAGX) cites major subsequent events in delaying Q2 2026 10-Q - Stock Titan
Jaguar Health (JAGX) details 40.9M-share resale tied to $40M equity line - Stock Titan
Jaguar Health (JAGX) Ticks Up 2.22% to $0.96, Approaching Key Resistance at $1.01Cumulative Volume - dars.gov.et
Jaguar Health (JAGX) Secures $2 Million Holdback Payment from Fu - GuruFocus
Why is Jaguar Health stock gaining today? - Investing.com
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 - ACCESS Newswire
News by ACCESS Newswire on TradingView, 2026-08-05 - TradingView
After 12 Months, Crofelemer Cut Support Up to 48% in One MVID Patient - Stock Titan
Why is Jaguar Health stock gaining today? By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Consolidates at $1.0: Support and Resistance Define Trading RangeRVOL Spike - vinanet.vn
Jaguar Health (JAGX) Holds at $1.00 as Tight Trading Range Defines Key Levels to WatchVolatility Surface - dars.gov.et
Jaguar Health (JAGX) Dips 3.56% to $1.00, Pressing Key Support LevelSector Neutral Pair - Vinanet
Jaguar Health (JAGX) Highlights Market Potential of Neonorm Dog Amidst Challenging Valuation - GuruFocus
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - Yahoo! Finance Canada
Jaguar Health Inc (JAGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jaguar Health Inc (JAGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jaguar Health Inc (JAGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jaguar Health, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):